Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 19, Issue 2, 2016, Pages 145-150

  Rybicki, B A ^a   Kryvenko, O N ^b   Wang, Y ^a   Jankowski, M ^a   Trudeau, S ^a   Chitale, D A ^a   Gupta, N S ^a   Rundle, A ^c   Tang, D ^c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; BIOLOGICAL MARKER;

AFRICAN AMERICAN; ARTICLE; BENIGN TUMOR; CANCER RISK; CASE CONTROL STUDY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; CAUCASIAN; COMPLICATION; ETHNIC GROUP; ODDS RATIO; PATHOLOGY; PREVALENCE; PROSTATE; PROSTATIC NEOPLASMS; RISK;

AFRICAN AMERICANS; BIOMARKERS; CASE-CONTROL STUDIES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; ODDS RATIO; PREVALENCE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATITIS; RISK;

EID: 84955255795     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.54     Document Type: Article

References (39)

1. Theodorou C, Becopoulos T. Prostatitis. Prostate Cancer Prostatic Dis 1999; 2: 234-240
2. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236-237
3. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001; 87: 797-805
4. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998; 51: 578-584
5. Wu C, Zhang Z, Lu Z, Liao M, Zhang Y, Xie Y, et al. Prevalence of and risk factors for asymptomatic in fl ammatory (NIH-IV) prostatitis in Chinese men. PLoS One 2013; 8: e71298
6. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83
7. Jiang J, Li J, Yunxia Z, Zhu H, Liu J, Pumill C. The role of prostatitis in prostate cancer: meta-analysis. PLoS One 2013; 8: e85179
8. Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP, et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One 2010; 5: e8736
9. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. Epidemiology 2004; 15: 93-99
10. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001; 165: 842-845
11. Rizzo M, Marchetti F, Travaglini F, Trinchieri A, Nickel JC. Prevalence, diagnosis and treatment of prostatitis in Italy: a prospective urology outpatient practice study. BJU Int 2003; 92: 955-959
12. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis 2010; 50: 1641-1652
13. Delongchamps NB, De la RG, Chandan V, Jones R, Sunheimer R, Threatte G, et al. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer?. J Urol 2008; 179: 1736-1740
14. Kryvenko ON, Jankowski M, Chitale DA, Tang D, Rundle A, Trudeau S, et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol 2012; 25: 1023-1032
15. Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawao M. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/ml. Urology 2008; 72: 1194-1197
16. Karakiewicz PI, Benayoun S, Begin LR, Duclos A, Valiquette L, McCormack M, et al. Chronic inflammation is negatively associated with prostate cancer and highgrade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007; 61: 425-430
17. Lee AG, Choi YH, Cho SY, Cho IR. A prospective study of reducing unnecessary prostate biopsy in patients with high serum prostate-specific antigen with consideration of prostatic inflammation. Korean J Urol 2012; 53: 50-53
18. Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014; 23: 847-856
19. Zhao C, Venigalla S, Miyamoto H. Chronic inflammation on initial benign prostate biopsy is a negative predictor of subsequent cancer detection. Pathol Int 2012; 62: 774-776
20. Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S. Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol 2011; 185: 1722-1727
21. Yli-Hemminki TH, Laurila M, Auvinen A, Maattanen L, Huhtala H, Tammela TL, et al. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 2013; 112: 735-741
22. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 2014; 120: 190-196
23. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin 2013; 63: 151-166
24. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, et al. Prostatespecific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997; 89: 134-138
25. Tewari A, Horninger W, Badani KK, Hasan M, Coon S, Crawford ED, et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2005; 96: 29-33
26. Kwak C, Ku JH, Kim T, Park DW, Choi KY, Lee E, et al. Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer. Urology 2003; 62: 854-859
27. Fowler JE Jr, Bigler SA, Kilambi NK, Land SA. Relationships between prostatespecific antigen and prostate volume in black and white men with benign prostate biopsies. Urology 1999; 53: 1175-1178
28. Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst 1998; 90: 756-760
29. Sarma AV, McLaughlin JC, Wallner LP, Dunn RL, Cooney KA, Schottenfeld D, et al. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol 2006; 176: 1108-1113
30. John EM, Whittemore AS, Wu AH, Kolonel LN, Hislop TG, Howe GR, et al. Vasectomy and prostate cancer: results from a multiethnic case-control study. J Natl Cancer Inst 1995; 87: 662-669
31. Patel DA, Bock CH, Schwartz K, Wenzlaff AS, Demers RY, Severson RK. Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case-control study in Wayne County, Michigan. Cancer Causes Control 2005; 16: 263-273
32. Gui-Zhong L, Libo M, Guanglin H, Jianwei W. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol 2011; 43: 295-301
33. Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol 2007; 39: 859-863
34. Nickel JC. Lower urinary tract symptoms associated with prostatitis. Can Urol Assoc J 2012; 6 (5 Suppl 2): S133-S135
35. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-981
36. Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31 (Suppl 1): S85-S90
37. Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007; 99: 1395-1400
38. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103: 117-128
39. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008; 68: 927-936